New Intranasal Vaccine Shows Promise Against Tuberculosis
New Intranasal Vaccine Shows Promise Against Tuberculosis
Tuberculosis (TB) remains a major global health challenge, causing millions of deaths annually.
While the current BCG vaccine helps protect children, it is less effective for adults and fails to provide strong immunity in the lungs.
Recently, researchers from Johns Hopkins Medicine have made an exciting breakthrough by developing a new <span class="annotated" data-start="238" data-end="264" data-value="therapeutic DNA vaccine">therapeutic DNA vaccine</span> for TB.
Unlike traditional vaccines that aim only to prevent infection, this novel treatment is designed to target drug-tolerant "persister" bacteria, which are the main culprits behind disease relapse.
What makes this approach particularly innovative is its delivery method: it is administered <span class="annotated" data-start="455" data-end="465" data-value="intranasally">intranasally</span>.
By delivering the vaccine directly into the nasal passages, scientists hope to stimulate a robust immune response specifically in the lungs, the primary site of TB infection.
